Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-15
    E.g., 2018-10-15

Archive Search

1 results
10:49 AM, May 11, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Arcus reports Phase I safety data for cancer candidate AB928

in a Phase I trial showing that single and multiple ascending doses of cancer candidate AB928
Chicago. The company plans to report final data from the double-blind, placebo-controlled trial in mid-2018. AB928
ADORA2A) and ADORA2B antagonist. Arcus also plans to start Phase I/Ib testing in mid-2018 of AB928